# A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

> **NCT03718624** · PHASE2 · UNKNOWN · sponsor: **Hebei Medical University** · enrollment: 36 (estimated)

## Conditions studied

- Gastric Cancer With Positive Exfoliative Cancer Cells

## Interventions

- **DRUG:** apatinib
- **DRUG:** paclitaxel
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT03718624
- **Lead sponsor:** Hebei Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-30
- **Primary completion:** 2019-10-30
- **Final completion:** 2020-10-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03718624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03718624, "A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03718624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*